Description: Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Home Page: evgen.com
EVG Technical Analysis
Alderley Park, Block 24
Nether Alderley,
SK10 4TG
United Kingdom
Phone:
44 16 2546 6591
Officers
| Name | Title |
|---|---|
| Dr. Huw Jones BSc, Ph.D. | CEO & Exec. Director |
| Mr. Richard Anthony Moulson | CFO & Exec. Director |
| Dr. Helen Kuhlman | Chief Bus. Officer |
| Dr. Glen Clack FFPM, M.D. | Chief Medical Officer |
| Ms. Liz Jenkins | Regulatory Consultant |
| Prof. Albena Dinkova-Kostova | Independent Scientific Advisor |
| Prof. Giovanni Mann | Independent Scientific Advisor |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0606 |
| Price-to-Sales TTM: | 71.6976 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 9 |